Skip to main content

Drug Interactions between Bevyxxa and revakinagene taroretcel

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

betrixaban revakinagene taroretcel ophthalmic

Applies to: Bevyxxa (betrixaban) and revakinagene taroretcel

ADJUST DOSING INTERVAL: Coadministration of revakinagene taroretcel ophthalmic with drugs that can affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextrans, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of vitreous hemorrhage, which may result in temporary vision loss.

MANAGEMENT: The manufacturer of revakinagene taroretcel ophthalmic recommends temporarily interrupting antithrombotic medications before revakinagene taroretcel implantation. Patients should be advised to promptly report any signs of blurred vision, vision loss, floaters, or flashes of light. Clinicians should consult relevant literature, local and national treatment guidelines, and package labeling for further guidance.

References (1)
  1. (2025) "Product Information. Encelto (revakinagene taroretcel ophthalmic)." Neurotech Pharmaceuticals, Inc

Drug and food/lifestyle interactions

Moderate

betrixaban food/lifestyle

Applies to: Bevyxxa (betrixaban)

ADJUST DOSING INTERVAL: Food reduces the oral bioavailability of betrixaban. When administered with a low-fat (900 calories; 20% fat) or high-fat (900 calories; 60% fat) meal, betrixaban peak plasma concentration (Cmax) and systemic exposure (AUC) decreased relative to administration in the fasting state by an average of 70% and 61%, respectively, with the low-fat meal and 50% and 48%, respectively, with the high-fat meal. The effect of food on betrixaban pharmacokinetics could be observed for up to 6 hours after meal intake.

MANAGEMENT: The manufacturer recommends taking betrixaban at the same time each day with food.

References (1)
  1. (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer